Trade Coherus BioSciences - CHRS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.08 |
| Open | 1.03 |
| 1-Year Change | -49.51% |
| Day's Range | 1 - 1.14 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 20, 2024 | 1.08 | 0.28 | 35.00% | 0.80 | 1.10 | 0.79 |
| Nov 19, 2024 | 0.80 | 0.04 | 5.26% | 0.76 | 0.80 | 0.73 |
| Nov 18, 2024 | 0.75 | 0.02 | 2.74% | 0.73 | 0.77 | 0.72 |
| Nov 15, 2024 | 0.72 | -0.05 | -6.49% | 0.77 | 0.77 | 0.68 |
| Nov 14, 2024 | 0.75 | -0.04 | -5.06% | 0.79 | 0.79 | 0.75 |
| Nov 13, 2024 | 0.76 | -0.05 | -6.17% | 0.81 | 0.85 | 0.75 |
| Nov 12, 2024 | 0.80 | 0.04 | 5.26% | 0.76 | 0.86 | 0.75 |
| Nov 11, 2024 | 0.76 | -0.03 | -3.80% | 0.79 | 0.82 | 0.75 |
| Nov 8, 2024 | 0.80 | -0.01 | -1.23% | 0.81 | 0.83 | 0.75 |
| Nov 7, 2024 | 0.81 | 0.04 | 5.19% | 0.77 | 0.93 | 0.74 |
| Nov 6, 2024 | 0.68 | -0.04 | -5.56% | 0.72 | 0.73 | 0.67 |
| Nov 5, 2024 | 0.70 | 0.05 | 7.69% | 0.65 | 0.71 | 0.64 |
| Nov 4, 2024 | 0.64 | -0.06 | -8.57% | 0.70 | 0.72 | 0.64 |
| Nov 1, 2024 | 0.69 | -0.03 | -4.17% | 0.72 | 0.73 | 0.69 |
| Oct 31, 2024 | 0.72 | -0.01 | -1.37% | 0.73 | 0.73 | 0.70 |
| Oct 30, 2024 | 0.72 | 0.00 | 0.00% | 0.72 | 0.75 | 0.71 |
| Oct 29, 2024 | 0.72 | 0.02 | 2.86% | 0.70 | 0.73 | 0.69 |
| Oct 28, 2024 | 0.69 | -0.08 | -10.39% | 0.77 | 0.79 | 0.69 |
| Oct 25, 2024 | 0.76 | -0.02 | -2.56% | 0.78 | 0.79 | 0.76 |
| Oct 24, 2024 | 0.77 | -0.02 | -2.53% | 0.79 | 0.81 | 0.77 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Coherus BioSciences Company profile
About Coherus Biosciences Inc
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. It operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences Co., Ltd., CIMERLI, a Lucentis biosimilar candidate in-licensed for commercial rights in the United States and Canada from Bioeq, and a bevacizumab (Avastin) biosimilar in-licensed for commercial rights in the United States from Innovent Biologics (Suzhou) Co., Ltd. It is also developing an internal immuno-oncology pipeline in preclinical and translational science, bioinformatics, analytical characterization, process science engineering, and clinical-regulatory development and commercialization.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Coherus Biosciences Inc revenues decreased 31% to $326.6M. Net loss totaled $287.1M vs. income of $132.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Research and development increase from $128.9M to $344.4M (expense), General and administrative increase of 20% to $138.1M (expense).
| Industry: | Bio Therapeutic Drugs |
C/O Dennis M. Lanfear
201 Redwood Shores Parkway, Suite 200
REDWOOD CITY
CALIFORNIA 94065
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com